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ABSTRACT
Diabetes mellitus is the 7th leading cause of death in the United States, comprising about
10% of the population. With intermittent fasting gaining popularity in the media as a method to
lose weight and control chronic illness, patients with diabetes would likely turn to any of the
fasting methods in order to better manage their disease. However, there is a paucity of
information to support whether intermittent fasting is an effective method to control diabetes, in
conjunction with lifestyle modifications and anti-diabetic pharmacotherapy. This review sought
to identify clinically relevant human studies that provide evidence that intermittent fasting is
beneficial for those who suffer from type 1 or type 2 diabetes. A systematic review of the
published literature was performed using PRISMA protocol in order to identify clinical trials that
evaluated the effects of fasting in patients with type 1 or type 2 diabetes, specifically focusing on
body weight (kg), hemoglobin A1C (%), and blood plasma glucose levels (mmol/L). Four
randomized controlled trials and one case report of fasting in adults on anti-diabetic therapy with
diabetes were identified. Improvements in weight, A1C, and/or fasting plasma glucose were
identified in all of the studies. Patients may approach their health care providers with the desire
to utilize fasting as an alternative to effectively manage their diabetes. Providers can use the
studies included in this review as well as others that are available as a guide in order to make
proper recommendations and monitor their patients safely. However, more studies should be
performed in order to make accurate claims regarding the long-term effects of intermittent
fasting among patients with diabetes.
KEYWORDS: diabetes mellitus, intermittent fasting, alternate-day fasting, intermittent energy
restriction, time-restricted feeding, intermittent dieting, periodic fasting
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INTRODUCTION
Fasting, an ancient practice, has recently gained popularity in mainstream media as a
means to lose weight and control chronic illness1, 2. Diabetes mellitus, affecting about 10% of the
US population, is a chronic condition characterized by hyperglycemia due to insulin resistance or
deficiency3. Diabetes may require intensive lifestyle modifications and/or pharmacological
management, resulting in long-term end-organ damage if left untreated3. Any of the intermittent
fasting (IF) regimens may seem attractive to patients with either type 1 or type 2 diabetes if
typical anti-diabetic therapies become too costly, cause adverse effects, or fail.
IF describes eating patterns that cycle between feeding and fasting periods that specify
when to eat, rather than what to eat, with the end goal of caloric restriction1, 2. Common IF eating
patterns include time-restricting feeding, in which energy intake is restricted for consecutive
hours in a day, alternate-day fasting, in which energy intake is restricted every other day, and
modified fasting, in which energy intake is restricted to any two or three days of the week1,3.
Peer-reviewed human IF studies are limited while a majority of the information is written
by health gurus or is based on rat studies1. Several studies show that IF is effective for weight
loss in overweight and obese adults4-7. Trial data on fasting patients with diabetes is scarce. A
12-week randomized control trial by Varady et al (2013) demonstrated a 6% decrease in fasting
glucose levels in the alternate-day fasting group compared to the control group with no
restrictions8. Another randomized control trial by Klempel et al (2012) showed reductions in
glucose and insulin levels (P<0.05) in an 8-week IF study6. Both studies had subjects with
varying body mass indices (BMI 20-39.9 kg/m2) who were non-diabetic. These results show
promise for the use of therapeutic fasting, but more studies should be performed in patients with
diabetes to fully understand IF as a diet strategy.
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The objective of this systematic review is to utilize the limited data to provide
recommendations on how to safely monitor patients with diabetes who want to try IF. Religious
fasting regimens and animal studies will not be included.
METHODS
Database Search Strategy
A systematic review of the literature was performed using electronic databases for
published, peer-review articles in English. Major databases that were used in this review were
PubMed, Science Direct, CINAHL Plus, and Cochrane Collection Plus. Searches were
performed using keywords “diabetes mellitus” in combination with either “intermittent fasting,”
“alternate-day fasting,” “intermittent energy restriction,” “time-restricted feeding,” “intermittent
dieting,” or “periodic fasting.” Reference lists of selected articles were also inspected due to the
limited number of articles that resulted during the search. Titles of studies were critiqued by
looking for any keyword combination. Of those selected, the “Methods” sections were screened
using the inclusion and exclusion criteria (see section on “Inclusion and Exclusion Criteria”).
The Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) protocol
was used in order to determine which studies were eligible to be included in the review.
Protocol Used
PRISMA, composed of a flowchart and a checklist, is an organized method to improve
the reporting quality of the papers included in this review9. The flowchart assists with the
identification, screening, eligibility, and inclusion process for papers being reviewed. The 27item checklist pertains to the quality of the content of a systematic review or meta-analysis,
including the title, abstract, methods, results, discussion, and funding. A total of 376 records
were identified through electronic database searches. The studies were compiled in a list and
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arranged in alphabetical order of the primary author. 79 duplicate studies were then removed by
manually reviewing the list. 297 records were left to be screened for relevancy of the title and
abstract (see “Inclusion and Exclusion Criteria” below). Of those, 267 papers were excluded due
to irrelevancy, leaving 30 full-text articles to be assessed for eligibility. 25 of those studies were
excluded for not meeting inclusion criteria, with a total of 5 studies included in the qualitative
synthesis.
Inclusion and Exclusion Criteria
The inclusion and exclusion criteria across the final papers that were selected had several
similarities. Inclusion criteria included adults over the age of 18 with type 1 or type 2 diabetes on
anti-diabetic therapy with an A1C > 6.5%. Exclusion criteria included animal studies, religious
fasting, pregnant and/or lactating subjects, and those with previous weight loss surgery. Studies
in which fasting glucose results were unavailable were not excluded due to the paucity of data.
Setting and Subjects
In both the 2016 and 2018 Carter et al studies, the participants were recruited to the
University of South Australia from the general population with the use of public
advertisements10,11. There were no differences of inclusion criteria between the two trials.
Participants from the Corley et al (2018) study were recruited from secondary care diabetes
clinics, local community networks, and primary care practices around New Zealand and then
attended the Centre for Endocrine, Diabetes, and Obesity Research at Wellington Hospital12. In
the Furmli et al (2018) study, a chart review took place in the Intensive Dietary Management
Clinic in Toronto, Canada, and was performed with the three case study patients who provided
verbal and written consent to participate13. Lastly, the subjects in the Overland et al (2017) study
were eligible to participate if they were adults with type 1 diabetes with a BMI of 25-40 who
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attended the Diabetes Centre at Royal Prince Alfred Hospital in Sydney, Australia14. Each study
obtained approval from their own respective ethics committees and all subjects were provided
informed written consent to proceed with the experiments.
RESULTS
Characteristics of subjects
Each study featured adult, overweight or obese subjects with preexisting type 1 or 2
diabetes that were being treated with anti-diabetic agents. Each study except one showed that the
subjects had a starting BMI of >25 and a baseline A1C of >6.5%. The three case subjects in
Furmli et al (2018) did not disclose their heights so BMI could not be obtained; however, initial
waist circumference ranged from 89-123 cm and weight ranged from 61-97.1 kg13. Each of the
subjects in the Furmli study also had comorbidities which included hyperlipidemia,
hypertension, chronic kidney disease, and renal cell carcinoma13. Subjects in the other four
studies did not have any diabetes-related organ damage or comorbidities other than overweight
or obesity10-12,14.
Recruitment/response
All five of the studies included in this review revealed similar findings, in that IF is
associated with significant decreases in body weight, A1C, and fasting plasma glucose levels
(Table 1). Decreases in body weight ranged from 3.3-13.3%10-14. In addition, all studies showed
significant improvement in A1C levels, with Corley et al (2018) showing the largest decreases
(-7.1% for the consecutive fasting group and -8.5% for the non-consecutive fasting group)12.
Corley et al (2018) also showed that IF was associated with a lower-than-expected and clinically
acceptable risk of hypoglycemia, when combined with weekly supervision, hypoglycemia
education, and medication reduction at baseline12. The most notable outcome in Furmli et al
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(2018) is that all subjects discontinued their insulin use completely13. Fasting glucose results
were only available in two studies, both showing significant decreases11,12. Improvements in
quality of life and enjoyment of the active participation in their diabetes management via fasting
was also noted by subjects12,13.

Table 1. Changes in body weight, A1C, and fasting glucose levels from baseline to end of studies.
Study

Type

N

Subjects

Carter et al
(2016)10

Pragmatic pilot
randomized trial

63

Adults; diagnosed with T2DM,
on anti-diabetic medication
BMI > 27
Avg A1C 7.3%

Carter et al
(2018)11

Randomized
non-inferiority
pilot study

97

Adults; diagnosed with T2DM,

Treatment/Control

Body
Weight

A1C

Fasting
Glucose

Moderate continuous energy
restriction

-5.9%

-0.7%

--

2-day severe energy restriction w/ 5
days of habitual eating

-5.9%

-0.7%

--

Continuous energy restriction diet

-5.0%

-0.5%

-11.8%

Intermittent energy restriction diet

-6.8%

-0.3%

-11.8%

Consecutive fast 2d/wk

-2.9%

-7.1%

-15.9%

Non-consecutive fast 2d/wk

-3.3%

-8.5%

-12.2%

Alternating 24hr-fast 3d/wk

-13.3%

-0.2%

--

Continuous moderate energy
restriction: -30% relative to weight
maintenance energy needs

-3.9%

-0.1%

--

Severe energy restriction: 2d/wk

-7.0%

-0.0%

--

on anti-diabetic medication
BMI > 27
Avg A1C 7.3%

Corley et al
(2018)12

Randomized
control trial

37

Adults; diagnosed with T2DM,
on anti-diabetic medication
BMI 30-45
Avg A1C 6.7-10%

Furmli et al
(2018)13

Case report

3

Adults; diagnosed with T2DM,
on anti-diabetic medication
Initial waist circumference: 89123 cm
Initial weight: 61-97.1 kg

Overland et
al (2017)14

Randomized
parallel group
pilot study

10

Adults; diagnosed with T1DM,
on insulin
BMI 25-40
Avg A1C 6.5-10%
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DISCUSSION
Main Findings
These studies show that when individuals with type 1 or type 2 diabetes on anti-diabetic
medications incorporate IF into their lifestyle, statistically significant decreases in body weight,
A1C, and fasting blood glucose occur (see Table 1). When comparing intermittent energy
restriction to continuous energy restriction, as in Carter et al (2016 and 2018) and Overland et al
(2017), decreases in body weight and A1C are similar10,11,14. This suggests that any of the IF
regimens could serve as a viable option for losing weight and lowering blood sugar levels. IF
may increase patient adherence since the primary focus is when to eat, as opposed to continuous
energy restriction, or caloric restriction, which limits the amount of calories eaten each day. In
the Corley et al (2018) study, there were no differences in the results between the consecutive
and the non-consecutive 2-day per week fast12. This suggests that a patient may fast everyday or
every other day and achieve the same results, depending on preference.
Comparison of Findings with those Reported in the Literature
A systematic review by Horne, Muhlestein, and Anderson15 showed that fasting was
associated with improvements in weight and other cardiovascular and metabolic parameters,
such as triglycerides, LDL-cholesterol particle size, and C-reactive protein. Patient populations
of each study varied including individuals who were healthy, obese, elderly, or had a diagnosis
of coronary artery disease or diabetes. Improved mood was also reported in two randomized
control trials. The overall results of the review seem promising in decreasing the risk of
cardiovascular disease, diabetes, and mental health conditions, but further studies need to be
performed on a larger scale to make more accurate claims.
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Strengths and Limitations
A limitation of this study is the scarcity of published literature regarding IF and its effects
in persons with diabetes. The fact that all of the studies identified in this review were published
within the last 4 years indicates this is an area of active interest and ongoing research. While
current, these studies are limited to populations in Australia, New Zealand, and Canada and may
not be generalizable. Another limitation is differences in the length of treatment for each study,
ranging from 12 weeks to 12 months. In addition, Furmli et al (2018) and Overland et al (2017)
had the smallest sample sizes, undermining the external validity of this review. Furthermore,
only one study involved subjects with type 1 diabetes while the other four studies had subjects
with type 2 diabetes.
Implications for Research
Future studies should take place in other countries for longer durations with larger sample
sizes. Collectively, these factors would help the data to be more generalizable and allow
clinicians to make more comprehensive recommendations for long-term fasting. More patients
with type 1 diabetes should be included so that proper guidelines can be made with regards to
fasting, insulin use, and the risk for hypoglycemia.
Implications for Clinical Practice
Educating patients on the benefits of IF may help control diabetes and wean the use of oral or
injectable anti-diabetic agents. Fasting might be appealing to patients who are averse to taking
medication and wish to avoid side effects. Medications can also be very costly, and IF is an
inexpensive intervention that can be done in a variety of ways, allowing patients to choose how
they fast based on personal preference. Since IF is a popular diet, providers need to know the
risks and the benefits before counseling and managing patients.
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In order for health care providers to optimally monitor patients with diabetes during
fasting, they should seek guidance from peer-reviewed articles. The American Diabetes
Association (ADA) does not have specific recommendations for patients with diabetes who want
to try IF. However, an article written by Al-Arouj et al (2010) released by the ADA provides
recommendations for religious fasting among patients with diabetes16. To avoid the risk of
hypoglycemia, the article stresses the importance of individualized treatment plans, frequent
blood glucose checks, and proper exercise and nutrition. Al-Arouj et al makes specific
recommendations regarding medication adjustments, depending on the type of anti-diabetic
medication the patient is taking16. Providers can use this article as a starting guide, as well as
another article by Grajower & Horne, which makes similar recommendations regarding
medication adjustments, but specifically for various IF regimens1.
With proper counseling and monitoring by health care providers, patients with diabetes
can live longer, healthier, and happier lives through fasting. Though these results seem
reassuring, future studies should be performed in order to provide proper recommendations
regarding the long-term effects of IF among patients with diabetes.
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